Skip to main content
. Author manuscript; available in PMC: 2024 Jul 1.
Published in final edited form as: Nat Rev Clin Oncol. 2022 Apr 28;19(7):471–485. doi: 10.1038/s41571-022-00633-1

Fig. 2 |. Drugging the PI3K pathway through the decades.

Fig. 2 |

Timeline summarizing phosphatidylinositol 3-kinase (PI3K) pathway inhibitor drug development. FDA-approved drugs and their indications are boxed. CLL, chronic lymphocytic leukaemia; FL, follicular lymphoma; HR, hormone receptor; MZL, marginal zone lymphoma; NETs, neuroendocrine tumours; PIKK, PI3K-related kinase; RCC, renal cell carcinoma; R/R, relapse and/or refractory; SLL, small lymphocytic lymphoma.